Developing a Self-Management Support Program for People with Rare Autoimmune Rheumatic Diseases
Led by University of the West of England · Updated on 2024-10-15
360
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are exploring how to develop a self-management and psychological support program for people living with rare autoimmune rheumatic diseases RAIRDs. These diseases, including systemic lupus erythematosus, vasculitis, scleroderma, myositis, and Sjogrens syndrome, are chronic, multi-system conditions that can be life-threatening and significantly impact quality of life. The study aims to gather diverse patient and healthcare team perspectives across the UK to shape a relevant and effective support program.
The study involves a series of focus groups with patients from different regions to collect views on support needs, followed by a UK-wide survey available both online and in paper form translated into the ten most spoken languages. The information gathered will be used to build and refine the support program by incorporating feedback from patients, healthcare professionals, and patient partners. This non-interventional, observational study focuses on understanding patient needs rather than testing a treatment.
Participants will engage in focus group discussions and complete surveys about their experiences and support preferences. The study measures self-management and efficacy using patient-reported outcome measures during the survey phase. Patient research partners with lived experience help guide the project and dissemination of findings through publications and presentations. The total involvement spans from focus groups through survey completion and collaborative program development, with ongoing contributions from patient partners.
CONDITIONS
Brief Title
Rare AutoImmune SElf-management Programme Development
Research Team
D
Dr J Robson
J
Jen Orme
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosis of a rare rheumatic condition by a hospital doctor or specialist, including lupus, systemic vasculitis, myositis, Sjogren syndrome (self-reported)
Ability to give informed consent, with translation support if needed
Adults aged 18 years or older
You will not qualify if you...
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Diagnostic Evaluation
Duration - Several weeks
Participants take part in focus groups to share their views on support needs for rare autoimmune rheumatic diseases.
6 focus group sessions (online)
Surveillance
Duration - Several months
Participants complete a UK-wide survey to assess support needs, available in multiple languages and formats.
Survey completion at participant's convenience
Long-term Monitoring
Duration - Ongoing until study completion
Feedback from survey and focus groups is used to develop and refine a self-management support programme with patient partners and healthcare teams.
Meetings and involvement activities as scheduled
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Phase 1 Study of TI-0032-III Injection CAR-T Cell Therapy for Adults with Relapsed or Resistant Autoimmune Diseases
Study on Safety and Effectiveness of YTS109 Cell Therapy in Adults with Relapsed or Refractory Autoimmune Diseases
Exploratory Study of YTS109 Cell Therapy for Adults Aged 18 to 65 With Relapsed or Refractory Autoimmune Diseases Including SLE, Sjogrens Syndrome, and Rheumatoid Arthritis
Long-Term Follow-Up Study for Adults Previously Treated with KYV-101 CAR T-Cell Therapy
Phase 1 Study of FT819 Treatment for Moderate to Severe B-cell Mediated Autoimmune Diseases Including Lupus, Vasculitis, Myositis, and Systemic Sclerosis
Phase 12 Study Evaluating PRO-203 Injection in Healthy Adults and Adults With Systemic Sclerosis
Phase 1b2a Study to Evaluate Budoprutug Safety and Effects in Adults With Active Systemic Lupus Erythematosus
Study of C-CAR168, a CAR-T Cell Therapy Targeting CD20 and BCMA, for Adults with Autoimmune Diseases Resistant to Standard Treatment
Phase IbIIa Study of GR1803 Injection for Adults with Systemic Lupus Erythematosus
Evaluating Safety, Tolerability, and Effectiveness
Phase 1 Study of OL-108 CAR-T Cell Therapy for Adults with Relapsed or Refractory Autoimmune Diseases Including SLE, IIM, SSc, and AAV
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971-2011: a population-based study.
Manuela Quaresma, Michel P Coleman, Bernard Rachet